prostate cancer
play

PROSTATE CANCER Mr. Jawad Islam MBBS, MSc, FRCS(Ed), FEBU, FRCS(Urology) Consultant Urologist People Centred Positive Compassion Excellence Where is prostate located and what is its function? What is prostate cancer? How common

0 downloads 4 Views 594 KB Size Report
  1. PROSTATE CANCER Mr. Jawad Islam MBBS, MSc, FRCS(Ed), FEBU, FRCS(Urology) Consultant Urologist People Centred Positive Compassion Excellence

  2. • Where is prostate located and what is its function? • What is prostate cancer? • How common is prostate cancer? • What causes it? • What are the risk factors? • Can it be prevented? • Tests to find early prostate cancer? • How you stage prostate cancer? • What treatments are available? People Centred Positive Compassion Excellence

  3. Prostatecanceruk.org People Centred Positive Compassion Excellence

  4. People Centred Positive Compassion Excellence

  5. Function & problems of prostate • It produces fluid which forms the part of semen. • THREE main problems Benign prostate hyperplasia Prostatitis Prostate cancer People Centred Positive Compassion Excellence

  6. What is prostate cancer? • Every cell is dividing in an orderly fashion and in a controlled manner. • When cell division becomes uncontrolled abnormal cells are produced - cancer cells “GROWTH OF ABNORMAL CELLS” Prostate cancer • Cancer cells invade & damage normal tissue People Centred Positive Compassion Excellence

  7. How common is prostate cancer? • Most common cancer in male in UK. • 40,000 new cases diagnosed every year (110 cases/day) • 250,000 men living with prostate cancer. • Worldwide, 1.11 million cases diagnosed in 2012. • Lifetime risk: 1 in 8 Prostatecanceruk.org, cancerresearchuk.org People Centred Positive Compassion Excellence

  8. How many die from Prostate cancer? • Second most common cause of death after lung cancer. • 10,800 men died in 2012 (30 every day) • 1970 ---- 4 in 10 survived beyond 5 years • 2012 ---- 8 in 10 Survived beyond 5 years cancerresearchuk.org People Centred Positive Compassion Excellence

  9. What causes prostate cancer? AGE RISK FACTORS People Centred Positive Compassion Excellence

  10. cancerresearchuk.org People Centred Positive Compassion Excellence

  11. RISK FACTORS • Family History Father, brother ---- 2 to 3 times Diagnosed <60 years --- 3 to 4 times Mother with Breast cancer BRCA2 gene ---- 5 to 7 times Inheritance of Faulty gene cancerresearchuk.org People Centred Positive Compassion Excellence

  12. RISK FACTORS • Black African ----- 2 to 3 times • Obesity • High calcium diet • vasectomy People Centred Positive Compassion Excellence

  13. SCREENING OF PROSTATE CANCER “Finding the disease when there are no s/s”. • Screening finds the cancers in early stage • Prostate cancer screening PSA (prostate specific antigen) DRE (digital rectal examination) People Centred Positive Compassion Excellence

  14. PSA • Made in prostate cells • Measured with Blood test • Normal Value <4ng/ml (Age dependent) • PSA can be increased in: Prostate cancer Prostatitis / UTI Benign Enlargement of prostate • Prostate specific but not cancer specific People Centred Positive Compassion Excellence

  15. DIGITAL RECTAL EXAMINATION • Lubricated gloved finger • Hardness, lump or bumps of prostate People Centred Positive Compassion Excellence

  16. PROSTATE CANCER SCREENING • PSA is prostate specific, not cancer specific. • PSA senstivity 80%, Specificity 40% • DRE ---- not very accurate People Centred Positive Compassion Excellence

  17. PROSTATE CANCER SCREENING • Many big trials (European, PLCO) • Tests are not accurate • Does not reduce mortality Hence not recommended in UK People Centred Positive Compassion Excellence

  18. PROSTATE BIOPSY People Centred Positive Compassion Excellence

  19. DIAGNOSIS Prostate Biopsy ADENOCARCINOMA PROSTATE GLEASON SCORE Low Grade 2 to 6 Moderate Grade 7 Severe Grade 8 to 10 People Centred Positive Compassion Excellence

  20. STAGING OF PROSTATE CANCER • Localized • Locally Advance • Metastatic People Centred Positive Compassion Excellence

  21. MRI PROSTATE People Centred Positive Compassion Excellence

  22. BONE SCAN People Centred Positive Compassion Excellence

  23. TREATMENT OPTIONS 1. ACTIVE SURVILLANCE 2. SURGERY 3. RADIOTHERAPY 4. HORMONAL TREATMENT People Centred Positive Compassion Excellence

  24. ACTIVE SURVILLANCE • Localised cancer • Low grade • Small volume • Monitor PSA • Repeat prostate biopsy in 1 year • Treatment if disease gets worse People Centred Positive Compassion Excellence

  25. SURGERY RADICAL PROSTATECTOMY • Localised prostate cancer • Low or moderate grade • Any volume People Centred Positive Compassion Excellence

  26. ROBOTIC RADICAL PROSTATECTOMY People Centred Positive Compassion Excellence

  27. LAPROSCOPIC RADICAL PROSTATECTOMY People Centred Positive Compassion Excellence

  28. RADIOTHERAPY • Locally advance cancer • Moderate to high grade • Any volume People Centred Positive Compassion Excellence

  29. BRACHYTHERAPY • Localised cancer • Low to moderate grade • Low Volume People Centred Positive Compassion Excellence

  30. HORMONE TREATMENT INJECTIONS • Metastatic cancer • Cuts of Testosterone • Usually given 3 monthly • Not curative People Centred Positive Compassion Excellence

  31. CHEMOTHERAPY • Metastatic disease not controlled with hormonal treatment. • Fit patients • Palliative care People Centred Positive Compassion Excellence

  32. PROSTATE CANCER Blackpool Victoria Hospital 2014 • Newly Diagnosed cases 173 • Ref. Routes (Fast track, consults, A&E) • TREATMENT 26 Patients Active Monitoring (BVH) 122 Hormone Therapy (BVH) 20 Radical Prostatectomy (Lanc Teaching Hospital) 2 Radiotherapy (Lancashire Teaching Hospitals) 3 Surgery (The Christie) People Centred Positive Compassion Excellence

  33. THANK YOU People Centred Positive Compassion Excellence

  34. Next Members Seminar Depression Awareness Week Wednesday, 15 th April 2015 10 – 11 am Lecture Theatre, Education Centre, BVH. People Centred Positive Compassion Excellence

Recommend Documents


overview of new therapies for ovarian cancer amp prostate
Overview of New Therapies for Ovarian

Overview of New Therapies for Ovarian Cancer & Prostate Cancer Jonathan

prostate cancer and oxygen prostate cancer and oxygen new
Prostate Cancer and Oxygen: Prostate

Prostate Cancer and Oxygen: Prostate Cancer and Oxygen: New Concepts and

development
Development By Dr. Walker Objectives

Arresting Prostate Cancer Development By Dr. Walker Objectives The many

post operative radiotherapy for operative radiotherapy
Post- -operative Radiotherapy for

Post- -operative Radiotherapy for operative Radiotherapy for Post Prostate

im proving outcom es for m en with prostate cancer
Im proving outcom es for m en with

Im proving outcom es for m en with prostate cancer Prostate Cancer Awareness

416 441 2131
(416)441-2131 ABOUT US Prostate cancer

Prostate Cancer Canada 2 Lombard Street 3 rd , Floor Toronto, ON M5C1M1

ironman international registry for men with advanced
IRONMAN: International Registry for Men

IRONMAN: International Registry for Men with Advanced Prostate Cancer

oncology imaging update
Oncology Imaging Update Ronan

Oncology Imaging Update Ronan McDermott Study Day March 30 th Brexit Day + 1

prostate cancer
Prostate Cancer Teaching Session Dr

Prostate Cancer Teaching Session Dr Anthony Joshua Kinghorn Cancer Centre

enterprise interest none
Enterprise | Interest None

Enterprise | Interest None Epigenetics and prostate cancer Defining the

the costs of cancer
The Costs of Cancer Addressing Patient

Cancer Action Network SM The Costs of Cancer Addressing Patient Costs

changing trends of presentation in colorectal carcinoma
Changing Trends of Presentation in

ORIGINAL ARTICLE Changing Trends of Presentation in Colorectal Carcinoma

cancer primary prevention
Cancer-Primary Prevention Chair: Anne

Meeting 4 Cancer-Primary Prevention Chair: Anne McTiernan Members: Peter

a highly potent and selective ret inhibitor
a Highly Potent and Selective RET

Clinical Activity and Tolerability of BLU-667, a Highly Potent and Selective

gastric cancer epidemiology including ge junction and
Gastric Cancer: Epidemiology (including

Gastric Cancer: Epidemiology (including GE junction) and clinical presentation

carcinomatous encephalitis as clinical presentation of
Carcinomatous encephalitis as clinical

See discussions, stats, and author profiles for this publication at:

meritus health systems 1 breast cancer breast cancer is
Meritus Health Systems 1 Breast

BREAST CANCER & LUNG CANCER Meritus Health Systems 1 Breast Cancer

patients with carcinoma of the lung a 14 year experience
Patients with Carcinoma of the Lung: A

Clinical Presentation and Management of Patients with Carcinoma of the Lung: A

jason ali
Jason Ali Specialist Registrar in

Jason Ali Specialist Registrar in Cardiothoracic Surgery, NNUH Director of

activating the
Activating the TG mutant RAS

Activating the TG mutant RAS neoantigen vaccine immune Dr. Erik Digman

cancer of unknown primary
Cancer of Unknown Primary Helen

Cancer of Unknown Primary Helen Rickards Acute Oncology and Cancer of

achievements poster presentations in 2019
Achievements: Poster Presentations in

Achievements: Poster Presentations in 2019 Leptomeningeal metastasis: A A